Science
Yakup Ergün: Adjuvant Therapy for Premenopausal Women with HR+/HER2- Breast Cancer
Yakup Ergün and Rebecca Shatsky/X

Yakup Ergün: Adjuvant Therapy for Premenopausal Women with HR+/HER2- Breast Cancer

Yakup Ergün, Medical Oncologist at Bower Hospital, shared on X:

“Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

Excellent review.”

To which, Rebecca Shatsky, Professor of Clinical Medicine at Professor of Clinical Medicine, added:

“Really fabulous figure here that summarize, which endocrine therapy combo should be used for each risk category in premenopausal HR+/Her2 negative breast cancer.”

Title: Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer

Authors: L. Licata, M. Mariani, A. Chiavassa, A. H. Partridge, C. Zanibelli, K. Jhaveri, K. Kalinsky, F. Patanè, C. Criscitiello, M. Lambertini, H. S. Rugo, M. M. Naldini, G. Notini, G. Viale, L. Pusztai, G. Bianchini.

Full article.

See gallery below.

Yakup Ergün

You can also read ‘PIK3CA Testing in Advanced HR+/HER2- Breast Cancer: New Expert Consensus Defines a Practical Path Forward‘

Yakup Ergün

A. Chiavassa A.H. Partridge Adjuvant Therapy C. Criscitiello C. Zanibelli cancer endocrine therapy F. Patanè G. Bianchini G. Notini G. Viale H S Rugo HR+/HER2- breast cancer K. Jhaveri K. Kalinsky L Pusztai L. Licata M. Lambertini M. M. Naldini M. Mariani OncoDaily Oncology Rebecca Shatsky Yakup Ergün